Review of Operations continued EXOSOME PROGRAM INOVIQ is developing a portfolio of EXO-NET capture tools and exosome diagnostics for detection, treatment selection and monitoring of cancer and other diseases. INOVIQ is engaging with academia and industry focused on exosome research to establish collaborations for the development of more accurate and reliable exosome diagnostics. The Company is progressing feasibility studies with various parties to evaluate the use of EXO-NET and NEURO-NET™ for both biomarker discovery and diagnostics. Successful feasibilities are expected to progress to the developmentstage for exosome diagnostics for cancer and neurological diseases over the next 12-months. Exosome research tools EXO-NET® is INOVIQ’s proprietary immuno-affinity capture technology designed for high-throughput isolation of exosomes in diagnostic applications. EXO-NET comprises a multi-layered matrix of capture antibodies coated onto magnetic beads that enable fast, efficient and specific exosome isolation that outperforms competitor products. EXO-NET can be customised to isolate sub-populations of exosomes for specific diseases. INOVIQ has developed NEURONET™ for isolation of brain-derived exosomes for use in neurological conditions. NEURO-NET™ comprises multiple antibodies to capture surface proteins found on exosomes released by brain cells including neurons, microglia, oligodendrocytes and astrocytes. Brain-derived exosomes have potential applications for brain cancer, neuropsychiatric disorders and neurodegenerative diseases. The Company plans to use NEURO-NET™ for both its own and partnered development of exosome diagnostics for neurological diseases. RESEARCH & DEVELOPMENT (R&D) PROGRESS INOVIQ technologies have the potential to deliver significant clinical and commercial benefits to patients, the healthcare system and shareholders. R&D activities during FY24 focused on expanding the exosome program across its research tools, diagnostics and discovery-stage therapeutics pipeline, and advancing the lead SubB2M diagnostics pipeline for monitoring cancer towards key development milestones. 10 INOVIQ Limited
RkJQdWJsaXNoZXIy MjE2NDg3